Ubiquitin ligases and the immune response

Annual Review of Immunology

Volumn 22, Issue , 2004, Pages 81-127

  Liu, Yun Cai ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

HECT; Immunity; Lymphocyte; RING; Ubiquitination

Indexed keywords

ADAPTOR PROTEIN; BINDING PROTEIN; CBL PROTEIN; CRK LIKE PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOMYCIN; PROTEASOME; PROTEIN C JUN; PROTEIN CBL B; PROTEIN INHIBITOR; PROTEIN ITCH; PROTEIN KINASE P13; PROTEIN P53; SUMO PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E1; UBIQUITIN PROTEIN LIGASE E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CATALYST; CELL MATURATION; DISEASE SEVERITY; ENZYME DEGRADATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UBIQUITINATION;

ANIMALS; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; HUMANS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES;

EID: 2542501657     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.012703.104813     Document Type: Review

References (314)

1. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. 1975. Isolation of a polypeptide that has lymphocyte-differentiating properties is probably represented universally in living cells. Proc. Natl. Acad. Sci. USA 72:11-15
2. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-79
3. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:503-33
4. Weissman AM. 2001. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:169-78
5. Schwartz AL, Ciechanover A. 1999. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50:57-74
6. Hicke L. 2001. Protein regulation by monoubiquitin. Nat. Rev. Mol. Cell Biol. 2:195-201
7. Janeway CA Jr, Medzhitov R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216
8. Medzhitov R, Janeway CA Jr. 1998. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10:351-53
9. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18:621-63
10. Ben-Neriah Y. 2002. Regulatory functions of ubiquitination in the immune system, Nat. Immunol. 3:20-26
11. Rock KL, Goldberg AL. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17:739-79
12. McGrath JP, Jentsch S, Varshavsky A. 1991. UBA 1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J. 10:227-36
13. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL. 1993. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 363:552-54
14. Johnson ES, Blobel G. 1997. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 272:26799-802
15. Schwarz SE, Matuschewski K, Liakopoulos D, Scheffner M, Jentsch S. 1998. The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme. Proc. Natl. Acad. Sci. USA 95:560-64
16. Muller S, Hoege C, Pyrowolakis G, Jentsch S. 2001. SUMO, ubiquitin's mysterious cousin. Nat. Rev. Mol. Cell Biol. 2:202-10
17. Hofmann RM, Pickart CM. 1999. Non-canonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96:645-53
18. Deng L, Wang C, Spencer E, Yang L, Braun A, et al. 2000. Activation of the IKappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-61
19. Li L, Cohen SN. 1996. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319-29
20. Babst M, Odorizzi G, Estepa EJ, Emr SD. 2000. Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1:248-58
21. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, et al. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65
22. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505
23. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. 1995. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 92:2563-67
24. Talis AL, Huibregtse JM, Howley PM. 1998. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273:6439-45
25. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, Howley PM. 1999. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc. Natl. Acad. Sci. USA 96:13738-43
26. Oda H, Kumar S, Howley PM. 1999. Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination. Proc. Natl. Acad. Sci. USA 96:9557-62
27. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, et al. 1997. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal Purkinje neurons. Nat. Genet. 17:75-78
28. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, et al. 1999. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell Biol. 19:1182-89
29. Pirozzi G, McConnell SJ, Uveges AJ, Carter JM, Sparks AB, et al. 1997. Identification of novel human WW domain-containing proteins by cloning of ligand targets. J. Biol. Chem. 272:14611-16
30. Sudol M. 1996. The WW module competes with the SH3 domain? Trends Biochem. Sci. 21:161-63
31. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. 1999. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399:784-88
32. Staub O, Dho S, Henry P, Correa J, Ishikawa T, et al. 1996. WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J. 15:2371-80
33. Freemont PS. 2000. RING for destruction? Curr. Biol. 10:R84-87
34. Joazeiro CA, Weissman AM. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549-52
35. Lupher ML Jr, Rao N, Eck MJ, Band H. 1999. The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol. Today 20:375-82
36. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. 1999. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286:309-12
37. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4:1029-40
38. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, et al. 1999. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger UbcH7. J. Biol. Chem. 274:31707-12
39. Zheng N, Wang P, Jeffrey PD, Pavletich NP. 2000. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102:533-39
40. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, et al. 1999. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 286:1321-26
41. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:8945-51
42. Tyers M, Willems AR. 1999. One ring to rule a superfamily of E3 ubiquitin ligases. Science 284:601-4
43. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, et al. 2002. Structure of the Cul1-Rbx1-Skp1-FboxSkp2 SCF ubiquitin ligase complex. Nature 416:703-9
44. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, et al. 2000. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol. 10:429-39
45. Ivan M, Kaelin WG Jr. 2001. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:27-34
46. Stebbins CE, Kaelin WG Jr, Pavletich NP. 1999. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455-61
47. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, et al. 1999. Rbx1, a component of the VHL tumor suppressor complex SCF ubiquitin ligase. Science 284:657-61
48. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-75
49. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423-27
50. 2 sensing. Science 292:464-68
51. 2-regulated prolyl hydroxylation. Science 292:468-72
52. Yu F, White SB, Zhao Q, Lee FS. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630-35
53. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP. 2002. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296:1886-89
54. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, et al. 2002. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417:975-78
55. Semenza GL. 2001. HIF-1 mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13:167-71
56. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, et al. 2002. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-68
57. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. 2002. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-55
58. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. 2003. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3:75-88
59. Hochstrasser M. 2001. SP-RING for SUMO: new functions bloom for a ubiquitin-like protein. Cell 107:5-8
60. Jackson PK. 2001. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15:3053-58
61. Johnson ES, Gupta AA. 2001. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106:735-44
62. Takahashi Y, Kahyo T, Toh EA, Yasuda H, Kikuchi Y. 2001. Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 276:48973-77
63. Kahyo T, Nishida T, Yasuda H. 2001. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 8:713-18
64. Schmidt D, Muller S. 2002. Members of the PIAS family act as SUMO ligases for c-Jun p53 and repress p53 activity. Proc. Natl. Acad. Sci. USA 99:2872-77
65. Nishida T, Yasuda H. 2002. PIAS1 PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J. Biol. Chem. 277:41311-17
66. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. 2002. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell Biol. 22:5222-34
67. Aasland R, Gibson TJ, Stewart AF. 1995. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem. Sci. 20:56-59
68. Capili AD, Schultz DC, Rauscher IF, Borden KL. 2001. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBO. J. 20:165-77
69. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. 2002. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9:945-56
70. Witowsky JA, Johnson GL. 2003. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 MKK4 and activation of the ERK1/2 and JNK pathways. J. Biol. Chem. 278:1403-6
71. Coscoy L, Ganem D. 2003. PHD domains and E3 ubiquitin ligases: viruses make the connection. Trends Cell Biol. 13:7-12
72. Koegl M, Hoppe T, Schlanker S, Ulrich HD, Mayer TU, Jentsch S. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635-44
73. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. 2001. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276:33111-20
74. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, et al. 2001. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276:42938-44
75. Murata S, Minami Y, Minami M, Chiba T, Tanaka K. 2001. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2:1133-38
76. Aravind L, Koonin EV. 2000. The U box is a modified RING finger - a common domain in ubiquitination. Curr. Biol 10:R132-34
77. Hustad CM, Perry WL, Siracusa LD, Rasberry C, Cobb L, et al. 1995. Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. Genetics 140:255-65
78. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. 1998. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 18:143-46
79. Fang D, Elly C, Gao B, Fang N, Altman Y, et al. 2002. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat. Immunol. 3:281-87
80. Li B, Tournier C, Davis RJ, Flavell RA. 1999. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J. 18:420-32
81. Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-73
82. Paul WE, Seder RA. 1994. Lymphocyte responses and cytokines. Cell 76:241-51
83. Conaway RC, Brower CS, Conaway JW. 2002. Emerging roles of ubiquitin in transcription regulation. Science 296:1254-58
84. Fuchs SY, Fried VA, Ronai Z. 1998. Stress-activated kinases regulate protein stability. Oncogene 17:1483-90
85. Angel P, Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072:129-57
86. Wagner EF. 2001. AP-1-Introductory remarks. Oncogene 20:2334-35
87. Macian F, Lopez-Rodriguez C, Rao A. 2001. Partners in transcription: NFAT and AP-1. Oncogene 20:2476-89
88. Treier M, Staszewski LM, Bohmann D. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-98
89. Thomas D, Tyers M. 2000. Transcriptional regulation: Kamikaze activators. Curr. Biol. 10:R341-43
90. Salghetti SE, Muratani M, Wijnen H, Futcher B, Tansey WP. 2000. Functional overlap of sequences that activate transcription signal and ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 97:3118-23
91. Salghetti SE, Caudy AA, Chenoweth JG, Tansey WP. 2001. Regulation of transcriptional activation domain function by ubiquitin. Science 293:1651-53
92. Musti AM, Treier M, Bohmann D. 1997. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275:400-2
93. Winberg G, Matskova L, Chen F, Plant P, Rotin D, et al. 2000. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell Biol 20:8526-35
94. Ikeda M, Ikeda A, Longan LC, Longnecker R. 2000. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 268:178-91
95. Merchant M, Swart R, Katzman RB, Ikeda M, IKeda A, et al. 2001. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function. Int. Rev. Immunol. 20:805-35
96. Ikeda M, Ikeda A, Longnecker R. 2001. PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J. Virol. 75:5711-18
97. Dykstra ML, Longnecker R, Pierce SK. 2001. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 14:57-67
98. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, et al. 1994. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180:1955-60
99. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 92:377-81
100. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2:223-38
101. Liu Y-C, Altman A. 1998. Cbl: complex formation and functional implications. Cell Signal. 10:377-85
102. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S. 1995. Cloning characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10:2367-77
103. Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, et al. 1999. cbl-3: a new mammalian cbl family protein. Oncogene 18:3365-75
104. Rao N, Lupher ML Jr, Ota S, Reedquist KA, Druker BJ, Band H. 2000. The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells. J. Immunol. 164:4616-26
105. Rao N, Ghosh AK, Ota S, Zhou P, Reddi AL, et al. 2001. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. EMBO J. 20:7085-95
106. Rao N, Miyake S, Reddi AL, Douillard P, Ghosh AK, et al. 2002. Negative regulation of Lck by Cbl ubiquitin ligase. Proc. Natl. Acad. Sci. USA 99:3794-99
107. Paolini R, Molfetta R, Beitz LO, Zhang J, Scharenberg AM, et al. 2002. Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fc-epsilon RI Syk in RBL cells. J. Biol. Chem. 277:36940-47
108. Rao N, Dodge I, Band H. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J. Leukoc. Biol. 71:753-63
109. Thien CB, Langdon WY. 2001. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2:294-307
110. Hicke L. 1999. Gettin' down with ubiquitin: turning off cell-surface receptors, transporters and channels. Trends Cell Biol. 9:107-12
111. de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J. 2001. c-Cbl ubiquitinates the EGF receptor at the plasma membrane remains receptor associated throughout the endocytic route. J. Cell Sci. 114:2167-78
112. Viola A, Lanzavecchia A. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104-6
113. Valitutti S, Muller S, Salio M, Lanzavecchia A. 1997. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J. Exp. Med. 185:1859-64
114. San Jose E, Borroto A, Niedergang F, Alcover A, Alarcon B. 2000. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity 12:161-70
115. Pantaleo G, Olive D, Poggi A, Pozzan T, Moretta L, Moretta A. 1987. Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation. J. Exp. Med. 166:619-24
116. Schonrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65:293-304
117. Cenciarelli C, Hou D, Hsu KC, Rellahan BL, Wiest DL, et al. 1992. Activation-induced ubiquitination of the T cell antigen receptor. Science 257:795-97
118. Cenciarelli C, Wilhelm KG Jr, Guo A, Weissman AM. 1996. T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation. J. Biol. Chem. 271:8709-13
119. Hou D, Cenciarelli C, Jensen JP, Nguygen HB, Weissman AM. 1994. Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines. J. Biol. Chem. 269:14244-47
120. Wang HY, Altman Y, Fang D, Elly C, Dai Y, et al. 2001. Cbl promotes ubiquitination of the T cell receptor{zeta} through an adaptor function of Zap-70. J. Biol. Chem. 276:26004-11
121. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, et al. 1998. Tissue hyperplasia enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell Biol. 18:4872-82
122. Naramura M, Kole HK, Hu R-J, Gu H. 1998. Altered thymic positive selection intracellular signals in Cbl-deficient mice. Proc. Natl. Acad. Sci. USA 95:15547-52
123. Panigada M, Porcellini S, Barbier E, Hoeflinger S, Cazenave PA, et al. 2002. Constitutive endocytosis and degradation of the pre-T cell receptor. J. Exp. Med. 195:1585-97
124. Niederberger N, Holmberg K, Alam SM, Sakati W, Naramura M, et al. 2003. Allelic exclusion of the TCR alpha-chain is an active process requiring TCR-mediated signaling c-Cbl. J. Immunol. 170:4557-63
125. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. 2002. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 3:1192-99
126. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. 2002. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416:183-87
127. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. 2002. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416:187-90
128. Schmidt A, Wolde M, Thiele C, Fest W, Kratzin H, et al. 1999. Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature 401:133-41
129. Haglund K, Shimokawa N, Szymkiewicz I, Dikic I. 2002. Cbl-directed monoubiquitination of CIN85 is involved in regulation of ligand-induced degradation of EGF receptors. Proc. Natl. Acad. Sci. USA 99:12191-96
130. Sosinowski T, Killeen N, Weiss A. 2001. The src-like adaptor protein downregulates the T cell receptor on cd4(+)cd8(+) thymocytes and regulates positive selection. Immunity 15:457-66
131. Holland SJ, Liao XC, Mendenhall MK, Zhou X, Pardo J, et al. 2001. Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel inhibitor of antigen receptor signaling. J. Exp. Med. 194:1263-76
132. Loreto MP, Berry DM, McGlade CJ. 2002. Functional cooperation between c-Cbl and Src-like adaptor protein 2 in the negative regulation of T-cell receptor signaling. Mol. Cell Biol. 22:4241-55
133. Wong ES, Fong CW, Lim J, Yusoff P, Low BC, et al. 2002. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J. 21:4796-808
134. Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. 2003. Sprouty fine-tunes EGF signaling through interlinked positive negative feedback loops. Curr. Biol. 13:297-307
135. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, Bar-Sagi D. 2003. hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr. Biol. 13:308-14
136. Chambers CA, Allison JP. 1999. Costimulatory regulation of T cell function. Curr. Opin. Cell Biol. 11:203-10
137. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, et al. 2000. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403:211-16
138. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216-20
139. Krawczyk C, Bachmaier K, Sasaki T, Jones RG, Snapper SB, et al. 2000. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13:463-73
140. Fang D, Wang H-Y, Fang N, Altman Y, Elly C, Liu Y-C. 2001. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J. Biol. Chem. 276:4872-78
141. Fang D, Liu Y-C. 2001. Proteolysis-independent regulation of phosphatidylinositol 3-kinase by Cbl-b-mediated ubiquitination in T cells. Nat. Immunol. 2:870-75
142. Bos JL. 1998. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J. 17:6776-82
143. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. 1997. Maintenance of human T cell anergy: blocking of EL-2 gene transcription by activated Rap1. Science 278:124-28
144. Chiang SH, Baumann CA, Kanzaki M, Thurmond DC, Watson RT, 2001. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410:944-48
145. Schmitt JM, Stork PJ. 2002. PKA phosphorylation of Src mediates cAMP's inhibition of cell growth via Rap1. Mol. Cell 9:85-94
146. Shao Y, Elly C, Liu YC. 2003. Negative regulation of Rap1 activation by the Cbl E3 ubiquitin ligase. EMBO Rep. 4:425-31
147. Liu Y-C, Gu H. 2002. Cbl and Cbl-b in T-cell regulation. Trends Immunol. 23:140-43
148. Elly C, Witte S, Zhang Z, Rosnet O, Lipokowitz S, et al. 1999. Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation. Oncogene 18:1153-62
149. Zhang W, Shao Y, Fang D, Huang J, Jeon MS, Liu YC. 2003. Negative regulation of TCR-mediated Crk-L-C3G signaling cell adhesion by Cbl-b. J. Biol. Chem. 278:23978-83
150. Kamradt T, Mitchison NA. 2001. Tolerance and autoimmunity. N. Engl. J. Med. 344:655-64
151. Walker LS, Abbas AK. 2002. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:11-19
152. Schwartz RH. 2003. T cell anergy. Annu. Rev. Immunol. 21:305-34
153. Fields PE, Gajewski TF, Fitch FW. 1996. Blocked Ras activation in anergic CD4+ T cells. Science 271:1276-78
154. Li W, Whaley CD, Mondino A, Mueller DL. 1996. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271:1272-76
155. Reedquist KA, Bos JL. 1998. Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes. J. Biol. Chem. 273:4944-49
156. Carey KD, Dillon TJ, Schmitt JM, Baird AM, Holdorf AD, et al. 2000. CD28 and the tyrosine kinase Lck stimulate mitogen-activated protein kinase activity in T cells via inhibition of the small G protein Rap1. Mol. Cell Biol. 20:8409-19
157. Sebzda E, Bracke M, Tugal T, Hogg N, Cantrell DA. 2002. Rap1A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling. Nat. Immunol. 3:251-58
158. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. 2002. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109:719-31
159. Spenser E, Jiang J, Chen ZJ. 1999. Signal-induced ubiquitination of IKappaBalpha by the F-box protein Slimb/beta-Trcp. Genes Dev. 13:284-94
160. Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, et al. 2003. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18:535-47
161. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501
162. O'Neill LA, Dinarello CA. 2000. The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation host defense. Immunol. Today 21:206-9
163. Shi CS, Kehrl JH. 2003. TNF-induced GCKR SAPK activation depends upon the E2/E3 complex Ubc13-Uev1A/TRAF2. J. Biol. Chem. 278:15429-34
164. Brown KD, Hostager BS, Bishop GA. 2002. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277:19433-38
165. Deveraux QL, Reed JC. 1999. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239-52
166. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. 2000. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288:874-77
167. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. 1997. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:6914-25
168. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. 2000. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275:26661-64
169. Suzuki Y, Nakabayashi Y, Takahashi R. 2001. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA 98:8662-67
170. Li X, Yang Y, Ashwell JD. 2002. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416:345-47
171. Silverman N, Maniatis T. 2001. NF-kappaB signaling pathways in mammalian insect innate immunity. Genes Dev. 15:2321-42
172. Ghosh S, Karin M. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl.):S81-96
173. Liou HC, Sha WC, Scott ML, Baltimore D. 1994. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol. Cell Biol. 14:5349-59
174. Xiao G, Harhaj EW, Sun SC. 2001. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7:401-9
175. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293:1495-99
176. Fong A, Sun SC. 2002. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2/p100. J. Biol. Chem. 277:22111-14
177. Fong A, Zhang M, Neely J, Sun SC. 2002. S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappaB2/p100. J. Biol. Chem. 277:40697-702
178. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, et al. 2002. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J. 21:5375-85
179. Claudio E, Brown K, Park S, Wang H, Siebenlist U. 2002. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3:958-65
180. Saijo K, Mecklenbrauker I, Santana A, Leitger M, Schmedt C, Tarakhovsky A. 2002. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J. Exp. Med. 195:1647-52
181. Lin L, DeMartino GN, Greene WC. 1998. Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell 92:819-28
182. Lin L, DeMartino GN, Greene WC. 2000. Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production. EMBO J. 19:4712-22
183. Orian A, Gonen H, Bercovich B, Fajerman I, Eytan E, et al. 2000. SCF(beta) (-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J. 19:2580-91
184. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, et al. 2003. betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol. Cell Biol. 23:402-13
185. Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C. 2001. Shared pathways of IkappaB kinase-induced SCF (betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha. Mol. Cell Biol. 21:1024-35
186. Amir RE, Iwai K, Ciechanover A. 2002. The NEDD8 pathway is essential for SCF(beta -TrCP)-mediated ubiquitination and processing of the NF-kappa B precursor p105. J. Biol. Chem. 277:23253-59
187. Massague J. 1998. TGF-beta signal transduction. Annu. Rev. Biochem. 67:753-91
188. Letterio JJ, Roberts AB. 1998. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16:137-61
189. Miyazono K, ten Dijke P, Heldin CH. 2000. TGF-beta signaling by Smad proteins. Adv. Immunol. 75:115-57
190. Gorelik L, Flavell RA. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2:46-53
191. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, et al. 1992. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-99
192. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, et al. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770-74
193. Moustakas A, Souchelnytskyi S, Heldin CH. 2001. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114:4359-69
194. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, et al. 1997. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:631-35
195. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, et al. 1997. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89:1165-73
196. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400:687-93
197. Lin X, Liang M, Feng XH. 2000. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J. Biol. Chem. 275:36818-22
198. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. 2001. Regulation of Smad degradation activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA 98:974-79
199. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, et al. 2001. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat. Cell Biol. 3:587-95
200. Stroschein SL, Bonni S, Wrana JL, Luo K. 2001. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev. 15:2822-36
201. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, et al. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 6:1365-75
202. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, et al. 2001. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 induces receptor degradation. J. Biol. Chem. 276:12477-80
203. Artavanis-Tsakonas S, Rand MD, Lake RJ. 1999. Notch signaling: cell fate control signal integration in development. Science 284:770-76
204. Robey E, Chang D, Itano A, Cado D, Alexander H, et al. 1996. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 87:483-92
205. Washburn T, Schweighoffer E, Gridley T, Chang D, Fowlkes BJ, et al. 1997. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 88:833-43
206. Deftos ML, He YW, Ojala EW, Bevan MJ. 1998. Correlating notch signaling with thymocyte maturation. Immunity 9:777-86
207. Deftos ML, Sevan MJ. 2000. Notch signaling in T cell development. Curr. Opin. Immunol. 12:166-72
208. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, et al. 1999. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10:547-58
209. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, et al. 1999. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 11:299-308
210. Izon DJ, Punt JA, Xu L, Karnell FG, Allman D, et al. 2001. Notch1 regulates maturation of CD4+ and CD8+ thymocytes by modulating TCR signal strength. Immunity 14:253-64
211. Yasutomo K, Doyle C, Miele L, Fuchs C, Germain RN. 2000. The duration of antigen receptor signalling determines CD4+ versus CD8+ T-cell lineage fate. Nature 404:506-10
212. Wolfer A, Bakker T, Wilson A, Nicolas M, Ioannidis V, et al. 2001. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat. Immunol. 2:235-41
213. Wolfer A, Wilson A, Nemir M, MacDonald HR, Radtke F. 2002. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. Immunity 16:869-79
214. Allman D, Punt JA, Izon DJ, Aster JC, Pear WS. 2002. An invitation to T and more: notch signaling in lymphopoiesis. Cell 109(Suppl.):S1-11
215. Osborne B, Miele L. 1999. Notch and the immune system. Immunity 11:653-63
216. Schmitt TM, Zuniga-Pflucker JC. 2002. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17:749-56
217. Cornell M, Evans DA, Mann R, Fostier M, Flasza M, et al. 1999. The Drosophila melanogaster Suppressor of deltex gene, a regulator of the Notch receptor signaling pathway, is an E3 class ubiquitin ligase. Genetics 152:567-76
218. Qiu L, Joazeiro C, Fang N, Wang HY, Elly C, et al. 2000. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J. Biol. Chem. 275:35734-37
219. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, et al. 2001. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 276:34371-78
220. Wu G, Lyapina S, Das I, Li J, Gurney M, et al. 2001. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol. Cell Biol. 21:7403-15
221. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. 2001. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J. Biol. Chem. 276:35847-53
222. Jehn BM, Dittert I, Beyer S, von der Mark K, Bielke W. 2002. c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. J. Biol. Chem. 277:8033-40
223. Lai EC, Deblandre GA, Kintner C, Rubin GM. 2001. Drosophila neuralized is a ubiquitin ligase that promotes the internalization and degradation of delta. Dev. Cell 1:783-94
224. Deblandre GA, Lai EC, Kintner C. 2001: Xenopus neuralized is a ubiquitin ligase that interacts with XDelta1 and regulates Notch signaling. Dev. Cell 1:795-806
225. Yeh E, Dermer M, Commisso C, Zhou L, McGlade CJ, Boulianne GL. 2001. Neuralized functions as an E3 ubiquitin ligase during Drosophila development. Curr. Biol. 11:1675-9
226. Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, et al. 2003. Mind Bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev. Cell 4:67-82
227. Wodarz A, Nusse R. 1998. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14:59-88
228. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, et al. 1999. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 18:2401-10
229. Latres E, Chiaur DS, Pagano M. 1999. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18:849-54
230. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, et al. 1999. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 9:207-10
231. van de Wetering M, de Lau W, Clevers H. 2002. WNT signaling and lymphocyte development. Cell 109(Suppl.):S13-19
232. Verbeek S, Izon D, Hofhuis F, Robanus-Maandag E, te Riele H, et al. 1995. An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature 374:70-74
233. Schilham MW, Wilson A, Moerer P, Benaissa-Trouw BJ, Cumano A, Clevers HC. 1998. Critical involvement of Tcf-1 in expansion of thymocytes. J. Immunol. 161:3984-91
234. Okamura RM, Sigvardsson M, Galceran J, Verbeek S, Clevers H, Grosschedl R. 1998. Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity 8:11-20
235. Gounari F, Aifantis I, Khazaie K, Hoeflinger S, Harada N, et al. 2001. Somatic activation of beta-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development. Nat. Immunol. 2:863-69
236. Ioannidis V, Beermann F, Clevers H, Held W. 2001. The beta-catenin-TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival. Nat. Immunol. 2:691-97
237. Polakis P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837-51
238. Matsuzawa SI, Reed JC. 2001. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell 7:915-26
239. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, et al. 2001. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7:927-36
240. Hu G, Fearon ER. 1999. Siah-1 N-terminal RING domain is required for proteolysis function, C-terminal sequences regulate oligomerization and binding to target proteins. Mol. Cell Biol. 19:724-32
241. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96:11364-69
242. Germani A, Bruzzoni-Giovanelli H, Fellous A, Gisselbrecht S, Varin-Blank N, Calvo F. 2000. SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis. Oncogene 19:5997-6006
243. Tiedt R, Bartholdy BA, Matthias G, Newell JW, Matthias P. 2001. The RING finger protein Siah-1 regulates the level of the transcriptional coactivator OBF-1. EMBO J. 20:4143-52
244. Amson RB, Nemani M, Roperch JP, Israeli D, Bougueleret L, et al. 1996. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc. Natl. Acad. Sci. USA 93:3953-57
245. Frew D, Dickins RA, Cuddihy AR, Del Rosario M, Reinhard C, et al. 2002. Normal p53 function in primary cells deficient for Siah genes. Mol. Cell Biol. 22:8155-64
246. Dickins RA, Frew IJ, House CM, O'Bryan MK, Holloway AJ, et al. 2002. The ubiquitin ligase component Siah1a is required for completion of meiosis I in male mice. Mol. Cell Biol. 22:2294-303
247. Ashcroft M, Vousden KH. 1999. Regulation of p53 stability. Oncogene 18:7637-43
248. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-21
249. Costello PS, Cleverley SC, Galandrini R, Henning SW, Cantrell DA. 2000. The GTPase rho controls a p53-dependent survival checkpoint during thymopoiesis. J. Exp. Med. 192:77-85
250. Boehme SA, Lenardo MJ. 1996. TCR-mediated death of mature T lymphocytes occurs in the absence of p53. J. Immunol. 156:4075-78
251. Grayson JM, Lanier JG, Altman JD, Ahmed R. 2001. The role of p53 in regulating antiviral T cell responses. J. Immunol. 167:1333-37
252. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27
253. Nakamura S, Roth JA, Mukhopadhyay T. 2000. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell Biol. 20:9391-98
254. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. 2000. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell Biol. 20:8458-67
255. Boyd SD, Tsai KY, Jacks T. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563-68
256. Gu J, Nie L, Wiederschain D, Yuan ZM. 2001. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol. Cell Biol. 21:8533-46
257. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. 2001. C-terminal ubiquitination of p53 contributes to nuclear export. Mol. Cell Biol. 21:8521-32
258. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. 2003. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell Biol. 23:462-72
259. Prives C, Manley JL. 2001. Why is p53 acetylated? Cell 107:815-18
260. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. 1999. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 96:13777-82
261. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, et al. 1999. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18:1805-14
262. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, et al. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-27
263. Wu Z, Earle J, Saito S, Anderson CW, Appella E, Xu Y. 2002. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell Biol. 22:2441-49
264. Li M, Luo J, Brooks CL, Gu W 2002. Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277:50607-11
265. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. 2002. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 277:30838-43
266. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, et al. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:6236-45
267. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, et al. 2003. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300:342-44
268. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. 2003. Parc: a cytoplasmic anchor for p53. Cell 112:29-40
269. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-91
270. Pamer E, Cresswell P. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol. 16:323-58
271. Villadangos JA, Ploegh HL. 2000. Proteolysis in MHC class II antigen presentation: Who's in charge? Immunity 12:233-39
272. Glynne R, Powis SH, Beck S, Kelly A, Kerr LA, Trowsdale J. 1991. A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 353:357-60
273. Hisamatsu H, Shimbara N, Saito Y, Kristensen P, Hendil KB, et al. 1996. Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J. Exp. Med. 183:1807-16
274. Gaczynska M, Rock KL, Goldberg AL. 1993. Gamma-interferon expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365:264-67
275. Cerundolo V, Benham A, Braud V, Mukherjee S, Gould K, et al. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human murine cells. Eur. J. Immunol. 27:336-41
276. Lelouard H, Gatti E, Cappello F, Gresser O, Camosseto V, Pierre P. 2002. Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature 417:177-82
277. Cox JH, Galardy P, Bennink JR, Yewdell JW. 1995. Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J. Immunol. 154:511-19
278. Yewdell JW, Anton LC, Bennink JR. 1996. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157:1823-26
279. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770-74
280. Reits EA, Vos JC, Gromme M, Neefjes J. 2000. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 404:774-78
281. DeLeo AB. 1998. p53-based immunotherapy of cancer. Crit. Rev. Immunol. 18:29-35
282. Dahl AM, Beverley PC, Stauss HJ. 1996. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157:239-46
283. Furman MH, Ploegh HL. 2002. Lessons from viral manipulation of protein disposal pathways. J. Clin. Invest. 110:875-79
284. Shamu CE, Flierman D, Ploegh HL, Rapoport TA, Chau V. 2001. Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol. Biol. Cell 12:2546-55
285. Kikkert M, Hassink G, Barel M, Hirsch C, van der Wal FJ, Wiertz E. 2001. Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. Biochem. J. 358:369-77
286. Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, et al. 2000. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13:365-74
287. Coscoy L, Ganem D. 2000. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. USA 97:8051-56
288. Coscoy L, Sanchez DJ, Ganem D. 2001. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155:1265-73
289. Boname JM, Stevenson PG. 2001. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 15:627-36
290. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG, Lehner PJ. 2002. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J. 21:2418-29
291. Lybarger L, Wang X, Harris MR, Virgin HWt, Hansen TH. 2003. Virus subversion of the MHC class I peptide-loading complex. Immunity 18:121-30
292. Mansouri M, Bartee E, Gouveia K, Hovey Nerenberg BT, Barrett J, et al. 2003. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J. Virol. 77:1427-40
293. Guerin JL, Gelfi J, Boullier S, Delverdier M, Bellanger FA, et al. 2002. Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 downregulation and defines scrapins, a new group of surface cellular receptor abductor proteins. J. Virol. 76:2912-23
294. Schubert U, Anton LC, Bacik I, Cox JH, Bour S, et al. 1998. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:2280-88
295. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. 1998. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1:565-74
296. Vogt VM. 2000. Ubiquitin in retrovirus assembly: actor or bystander? Proc. Natl. Acad. Sci. USA 97:12945-47
297. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, et al. 2000. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 97:13057-62
298. Patnaik A, Chau V, Wills JW. 2000. Ubiquitin is part of the retrovirus budding machinery. Proc. Natl. Acad. Sci. USA 97:13069-74
299. Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG. 2000. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. USA 97:13063-68
300. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. 2000. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl. Acad. Sci. USA 97:13871-76
301. Kikonyogo A, Bouamr F, Vana ML, Xiang Y, Aiyar A, et al. 2001. Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc. Natl. Acad. Sci. USA 98:11199-204
302. Yasuda J, Hunter E, Nakao M, Shida H. 2002. Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep. 3:636-40
303. Huang M, Orenstein JM, Martin MA, Freed EO. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-18
304. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, et al. 2001. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad. Sci. USA 98:7724-29
305. Pornillos O, Alam SL, Davis DR, Sundquist WI. 2002. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9:812-17
306. Demirov DG, Ono A, Orenstein JM, Freed EO. 2002. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc. Natl. Acad. Sci. USA 99:955-60
307. Katzmann DJ, Babst M, Emr SD. 2001. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 106:145-55
308. Martin-Serrano J, Zang T, Bieniasz PD. 2003. Role of ESCRT-I in retroviral budding. J. Virol. 77:4794-804
309. Pornillos O, Alam SL, Rich RL, Myszka DG, Davis DR, Sundquist WI. 2002. Structure and functional interactions of the Tsg101 UEV domain. EMBO J. 21:2397-406
310. Martin-Serrano J, Zang T, Bieniasz PD. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:1313-19
311. Timmins J, Schoehn G, Ricard-Blum S, Scianimanico S, Vernet T, et al. 2003. Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4. J. Mol. Biol. 326:493-502
312. Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN. 2003. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J. Virol. 77:1812-19
313. Liu J, Furukawa M, Matsumoto T, Xiong Y. 2002. NEDD8 modification of CUL1 dissociates p120(CAND1), an inhibitor of CUL1-SKP1 binding SCF ligases. Mol. Cell 10:1511-18
314. Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, et al. 2002. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cu11. Science 298:608-11